Reduced necrosis of dystrophic muscle by depletion of host neutrophils, or blocking TNFα function with Etanercept in mdx mice

Neuromuscular Disorders

Volumn 16, Issue 9-10, 2006, Pages 591-602

  Hodgetts, Stuart ^a   Radley, Hannah ^a   Davies, Marilyn ^a   Grounds, Miranda D ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Etanercept; Muscular dystrophy; Myofibre necrosis; Neutrophils; Therapy; TNF

Indexed keywords

ANTIINFLAMMATORY AGENT; CYTOKINE; DYSTROPHIN; ETANERCEPT; GRANULOCYTE ANTIBODY; INFLIXIMAB; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY RB6 8C5; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE EXACERBATION; DRUG MECHANISM; FEMALE; IMMUNOPATHOLOGY; INFLAMMATORY CELL; LEUKAPHERESIS; MOUSE; MUSCLE EXERCISE; MUSCLE NECROSIS; MUSCULAR DYSTROPHY; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; SARCOLEMMA;

ANIMALS; ANTIBODIES; DISEASE MODELS, ANIMAL; DOWN-REGULATION; DYSTROPHIN; FEMALE; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; MICE; MICE, INBRED MDX; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, DUCHENNE; NECROSIS; NEUTROPHILS; PHYSICAL CONDITIONING, ANIMAL; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33748519220     PISSN: 09608966     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nmd.2006.06.011     Document Type: Article

References (64)

1. Robertson T.A., Papadimitriou J.M., and Grounds M.D. Fusion of myogenic cells to the newly sealed region of damaged myofibres in skeletal muscle regeneration. Neuropathol Appl Neurobiol 19 (1993) 350-358
2. Beilharz M.W., Lareu R.R., Garrett K.L., Grounds M.D., and Fletcher S. Quantitation of muscle precursor cell activity in skeletal muscle by northern analysis of MyoD and myogenin expression - application to dystrophic (mdx) mouse muscle. Mol Cell Neurosci 3 (1992) 326-331
3. Grounds M.D., and Yablonka-Reuveni Z. Molecular and cell biology of skeletal muscle regeneration. Mol Cell Biol Hum Dis Ser 3 (1993) 210-256
4. McGeachie J.K., Grounds M.D., Partridge T.A., and Morgan J.E. Age-related changes in replication of myogenic cells in mdx mice: quantitative autoradiographic studies. J Neurol Sci 119 (1993) 169-179
5. Vilquin J.T., Brussee V., Asselin I., Kinoshita I., Gingras M., and Tremblay J.P. Evidence of mdx mouse skeletal muscle fragility in vivo by eccentric running exercise. Muscle Nerve 21 (1998) 567-576
6. Brussee V., Tardif F., and Tremblay J.P. Muscle fibers of mdx mice are more vulnerable to exercise than those of normal mice. Neuromuscul Disord 7 (1997) 487-492
7. Granchelli J.A., Avosso D.L., Hudecki M.S., and Pollina C. Cromolyn increases strength in exercised mdx mice. Res Commun Mol Pathol Pharmacol 91 (1996) 287-296
8. De Luca A., Pierno S., Liantonio A., et al. Enhanced dystrophic progression in mdx mice by exercise and beneficial effects of taurine and insulin-like growth factor-1. J Pharmacol Exp Ther 304 (2003) 453-463
9. De Luca A., Nico B., Liantonio A., et al. A multidisciplinary evaluation of the effectiveness of cyclosporine a in dystrophic mdx mice. Am J Pathol 166 (2005) 477-489
10. Payne E.T., Yasuda N., Bourgeois J.M., et al. Nutritional therapy improves function and complements corticosteroid intervention in mdx mice. Muscle Nerve 33 (2006) 66-77
11. Radley H.G., and Grounds M.D. Cromolyn administration (to block mast cell degranulation) reduces necrosis of dystrophic muscle in mdx mice. Neurobiol Dis 23 (2006) 387-397
12. Ehmsen J., Poon E., and Davies K. The dystrophin-associated protein complex. J Cell Sci 115 (2002) 2801-2803
13. Roberts R.G. Dystrophins and dystrobrevins. Genome Biol 2 (2001) S3006 REVIEW
14. Pizza F.X., McLoughlin T.J., McGregor S.J., Calomeni E.P., and Gunning W.T. Neutrophils injure cultured skeletal myotubes. Am J Physiol Cell Physiol 281 (2001) C335-C341
15. Nguyen H.X., and Tidball J.G. Interactions between neutrophils and macrophages promote macrophage killing of rat muscle cells in vitro. J Physiol 547 (2003) 125-132
16. McLoughlin T.J., Tsivitse S.K., Edwards J.A., Aiken B.A., and Pizza F.X. Deferoxamine reduces and nitric oxide synthase inhibition increases neutrophil-mediated myotube injury. Cell Tissue Res 313 (2003) 313-319
17. Nguyen H.X., and Tidball J.G. Expression of a muscle-specific, nitric oxide synthase transgene prevents muscle membrane injury and reduces muscle inflammation during modified muscle use in mice. J Physiol 550 part 2 (2003) 347-356
18. Cheung E.V., and Tidball J.G. Administration of the non-steroidal anti-inflammatory drug ibuprofen increases macrophage concentrations but reduces necrosis during modified muscle use. Inflamm Res 52 (2003) 170-176
19. Pizza F.X., Koh T.J., McGregor S.J., and Brooks S.V. Muscle inflammatory cells after passive stretches, isometric contractions and lengthening contractions. J Appl Physiol 92 (2002) 1873-1878
20. Porter J.D., Khanna S., Kaminski H.J., et al. A chronic inflammatory response dominates the skeletal muscle molecular signature in dystrophin-deficient mdx mice. Hum Mol Genet 11 (2002) 263-272
21. Porter J.D., Merriam A.P., Leahy P., et al. Temporal gene expression profiling of dystrophin-deficient (mdx) mouse diaphragm identifies conserved and muscle group-specific mechanisms in the pathogenesis of muscular dystrophy. Hum Mol Genet 13 (2004) 257-269
22. Spencer M.J., Montecino-Rodriguez E., Dorshkind K., and Tidball J.G. Helper (CD4(+)) and cytotoxic (CD8(+)) T cells promote the pathology of dystrophin-deficient muscle. Clin Immunol 98 (2001) 235-243
23. Gorospe J., Tharp M., Hinckley J., Kornegay J., and Hoffman E. A role for mast cells in the progression of Duchenne muscular dystrophy: Correlations in dystrophin-deficient humans, dogs, and mice. J Neurol Sci 122 (1994) 44-56
24. Nahirney P.C., Dow P.R., and Ovalle W.K. Quantitative morphology of mast cells in skeletal muscle of normal and genetically dystrophic mice. Anat Rec 247 (1997) 341-349
25. Tidball J.G. Inflammatory processes in muscle injury and repair. Am J Physiol Regul Integr Comp Physiol 288 (2005) R345-R353
26. Spencer M.J., Marino M.W., and Winckler W.M. Altered pathological progression of diaphragm and quadriceps muscle in TNF-deficient, dystrophin-deficient mice. Neuromuscul Disord 10 (2000) 612-619
27. Gosselin L.E., Barkley J.E., Spencer M.J., McCormick K.M., and Farkas G.A. Ventilatory dysfunction in mdx mice: impact of tumor necrosis factor-alpha deletion. Muscle Nerve 28 (2003) 336-343
28. Grounds M.D., and Torrisi J. Anti-TNFalpha (Remicade) therapy protects dystrophic skeletal muscle from necrosis. FASEB J 18 (2004) 676-682
29. Graninger W., and Smolen J. Treatment of rheumatoid arthritis by TNF-blocking agents. Int Arch Allergy Immunol 127 (2002) 10-14
30. Feldmann M., and Maini R.N. Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat Med 9 (2003) 1245-1250
31. Farahani P., Levine M., Gaebel K., Wang E.C., and Khalidi N. Community-based evaluation of etanercept in patients with rheumatoid arthritis. J Rheumatol 33 (2006) 665-670
32. Calabrese L. The yin and yang of tumor necrosis factor inhibitors. Cleve Clin J Med 73 (2006) 251-256
33. Gosselin L.E., and Martinez D.A. Impact of TNF-alpha blockade on TGF-beta1 and type I collagen mRNA expression in dystrophic muscle. Muscle Nerve 30 (2004) 244-246
34. Collins R.A., and Grounds M.D. The role of tumor necrosis factor-alpha (TNF-alpha) in skeletal muscle regeneration. Studies in TNF-alpha(-/-) and TNF-alpha(-/-)/LT-alpha(-/-) mice. J Histochem Cytochem 49 (2001) 989-1001
35. Kuru S., Inukai A., Kato T., Liang Y., Kimura S., and Sobue G. Expression of tumor necrosis factor-alpha in regenerating muscle fibers in inflammatory and non-inflammatory myopathies. Acta Neuropathol (Berl) 105 (2003) 217-224
36. Weisberg S.P., McCann D., Desai M., Rosenbaum M., Leibel R.L., and Ferrante Jr. A.W. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112 (2003) 1796-1808
37. Bortolotto S.K., Morrison W.A., Han X., and Messina A. Mast cells play a pivotal role in ischaemia reperfusion injury to skeletal muscles. Lab Invest 84 (2004) 1103-1111
38. Shavlakadze T., White J., Hoh J.F., Rosenthal N., and Grounds M.D. Targeted expression of insulin-like growth factor-I reduces early myofiber necrosis in dystrophic mdx mice. Mol Ther 10 (2004) 829-843
39. Archer J.D., Vargas C.C., and Anderson J.E. Persistent and improved functional gain in mdx dystrophic mice after treatment with L-arginine and deflazacort. FASEB J 20 (2006) 738-740
40. Sammels L.M., Bosio E., Fragall C.T., Grounds M.D., van Rooijen N., and Beilharz M.W. Innate inflammatory cells are not responsible for early death of donor myoblasts after myoblast transfer therapy. Transplantation 77 (2004) 1790-1797
41. Grounds M.D., Davies M., Torrisi J., Shavlakadze T., White J., and Hodgetts S. Silencing TNFalpha activity by using Remicade or Enbrel blocks inflammation in whole muscle grafts: an in vivo bioassay to assess the efficacy of anti-cytokine drugs in mice. Cell Tissue Res 320 (2005) 509-515
42. Wang X., Truong T., Billings P.B., Harris J.P., and Keithley E.M. Blockage of immune-mediated inner ear damage by etanercept. Otol Neurotol 24 (2003) 52-57
43. Sommer C., Schafers M., Marziniak M., and Toyka K.V. Etanercept reduces hyperalgesia in experimental painful neuropathy. J Peripher Nerv Syst 6 (2001) 67-72
44. Doherty K.R., and McNally E.M. Repairing the tears: dysferlin in muscle membrane repair. Trends Mol Med 9 (2003) 327-330
45. Clark I.A., Alleva L.M., Mills A.C., and Cowden W.B. Pathogenesis of malaria and clinically similar conditions. Clin Microbiol Rev 17 (2004) 509-539
46. Messina S., Bitto A., Aguennouz M., et al. Nuclear factor kappa-B blockade reduces skeletal muscle degeneration and enhances muscle function in Mdx mice. Exp Neurol 198 (2006) 234-241
47. Haslbeck K.M., Friess U., Schleicher E.D., et al. The RAGE pathway in inflammatory myopathies and limb girdle muscular dystrophy. Acta Neuropathol (Berl) 110 (2005) 247-254
48. Tidball J.G., and Wehling-Hendricks M. Evolving therapeutic strategies for Duchene muscular dystrophy: targeting downstream events. Pediatr Res 56 (2004) 831-841
49. Rando T.A. Role of nitric oxide in the pathogenesis of muscular dystrophies: a "two hit" hypothesis of the cause of muscle necrosis. Microsc Res Tech 55 (2001) 223-235
50. Pizza F.X., Hernandez I.J., and Tidball J.G. Nitric oxide synthase inhibition reduces muscle inflammation and necrosis in modified muscle use. J Leukoc Biol 64 (1998) 427-433
51. Wehling M., Spencer M.J., and Tidball J.G. A nitric oxide synthase transgene ameliorates muscular dystrophy in mdx mice. J Cell Biol 155 (2001) 123-131
52. Carter Y.M., Thomas R., Bargatze R., et al. Intracoronary E-/L-selectin blockade reduces neutrophil infiltration in heart transplantation. Ann Thorac Surg 74 (2002) 2064-2070 discussion 2070-2071
53. Wehling-Henricks M., Lee J.J., and Tidball J.G. Prednisolone decreases cellular adhesion molecules required for inflammatory cell infiltration in dystrophin-deficient skeletal muscle. Neuromuscul Disord 14 (2004) 483-490
54. Lieser M.J., Kozol R.A., and Tennenberg S.D. Interferon-gamma primes neutrophil-mediated gastric surface cell cytotoxicity. Am J Physiol 268 (1995) G843-G848
55. Merchant S.H., Gurule D.M., and Larson R.S. Amelioration of ischemia-reperfusion injury with cyclic peptide blockade of CAM-1. Am J Physiol Heart Circ Physiol 284 (2003) H1260-H1268
56. Toumi H., F'Guyer S., and Best T.M. The role of neutrophils in injury and repair following muscle stretch. J Anat 208 (2006) 459-470
57. Mitchell C.A., Grounds M.D., and Papadimitriou J.M. The genotype of bone marrow-derived inflammatory cells does not account for differences in skeletal muscle regeneration between SJL/J and BALB/c mice. Cell Tissue Res 280 (1995) 407-413
58. Mestas J., and Hughes C.C. Of mice and not men: differences between mouse and human immunology. J Immunol 172 (2004) 2731-2738
59. Strober J.B. Therapeutics in duchenne muscular dystrophy. NeuroRx 3 (2006) 225-234
60. Zwerina J., Hayer S., Tohidast-Akrad M., et al. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction. Arthritis Rheum 50 (2004) 277-290
61. Bushby K, Muntoni F, Urtizberea A, Hughes R, Griggs R. Report on the 124th ENMC International Workshop. Treatment of Duchenne muscular dystrophy; defining the gold standards of management in the use of corticosteroids. 2-4 April 2004, Naarden, The Netherlands. Neuromuscul Disord, 2004; 14: 526-534.
62. Biggar W.D., Harris V.A., Eliasoph L., and Alman B. Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscul Disord 16 (2006) 249-255
63. Hoffman E.P., Rao D., and Pachman L.M. Clarifying the boundaries between the inflammatory and dystrophic myopathies: insights from molecular diagnostics and microarrays. Rheum Dis Clin North Am 28 (2002) 743-757
64. Fisher I., Abraham D., Bouri K., Hoffman E.P., Muntoni F., and Morgan J. Prednisolone-induced changes in dystrophic skeletal muscle. FASEB J 19 (2005) 834-836